Global Health Limited · NSE:MEDANTA
Global Health — Q4 FY2025 Earnings Presentation
52 slides from Global Health's earnings presentation, May 16, 2025
Slide 1: Exchange filing cover letter for Investor Presentation
May 16, 2025 Ref:- GHL/2025-26/EXCH/19 The General Manager The Manager Dept. of Corporate Services Listing Department BSE Limited, National Stock Exchange of India Limited P J Towers, Dalal Street, Exchange Plaza, C-1, Block G, Mumbai - 400 001 Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Scri
Slide 2: Investor Presentation Q4 and FY2025
GLOBAL HEALTH LIMITED Dedicated to Life Investor Presentation Q4 and FY2025 5 15th May, 2025 1
Slide 3: Disclaimer
Disclaimer This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company’s strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties
Slide 4: Contents
Contents 01 FY2025: Year at a Glance 02 FY2025 Performance Update 03 Q4 FY2025 Performance Update 04 Project Update and Capex Plan 05 Medanta’s Journey, Purpose and Model of Healthcare 06 Annexures 3
Slide 5: FY2025: Year at a Glance
01 FY2025: Year at a Glance 4
Slide 6: One of the largest private hospital chains in North and East India
One of the largest private hospital chains in North and East India Serving over 400 million people in the States with Medanta facilities Gurugram; Largest single location private hospital in with operational Delhi; ~1,150 bed addition bed capacity of 1,440 Our Network planned with 750 beds in Pitamp
Slide 7: Executing strategic priorities with consistency
Executing strategic priorities with consistency Strengthening the core and building strong pipeline for growth Capacity Expansion Attract Best Talent Consolidated: Total 219 beds added during the year, 7.8% bed growth 119+ Doctors on-boarded in FY25 across Medanta network hospitals Gurugram: I
Slide 8: Advancing care: New equipment additions in FY2025
Advancing care: New equipment additions in FY2025 Providing the latest tools to enable our doctors to deliver the greatest care Medanta Gurugram Medanta Lucknow Magnetom Vida MRI System Da Vinci Xi Single robotic system Surgical Robot (Da Vinci) s with Paradigm Generator single console New Cath Lab-
Slide 9: FY2025 clinical achievements
FY2025 clinical achievements Continuing the legacy of clinical excellence Medanta Lucknow successfully performed the Group’s first CAR-T cell therapy, marking a significant milestone in advanced cancer care. Following this, Medanta Gurugram also conducted CAR-T cell therapy—an innovative treatment t
Slide 10: Merger of wholly owned subsidiary MHPL with GHL completed
Merger of wholly owned subsidiary MHPL with GHL completed in March 2025, with appointed date as 1st April, 2024 Current Structure Proposed merger of a wholly owned subsidiary MHPL with and into GHL by undertaking the scheme of amalgamation w.e.f. 1st April, 2024 Promoters Public MHPL runs a hosp
Slide 11: Consistent in pursuit of clinical excellence
Consistent in pursuit of clinical excellence Recognized as Best Private Hospital in India six years in a row by Newsweek For the Sixth year in a row, Medanta Gurugram has been recognised as India’s best private hospital in the prestigious ‘World's Best Hospitals 2025’ ranking by Newsweek Only Indian
Slide 12: FY2025 Performance Update
02 FY2025 Performance Update 11
Slide 13: FY2025 performance summary
FY2025 performance summary Revenue growth of 13% y-o-y, primarily led by increase in patient volumes. Announced first ever dividend of 25% (INR 0.50 per share) Adjusted PAT* INR 37,714 million INR 9,562 million INR 4,813 million INR 5,186 million Total Income Margin: 25.4% Margin: 12.8% Margin: 13.8
Slide 14: FY2025 performance summary
FY2025 performance summary Revenue growth of 13% y-o-y, primarily led by increase in patient volumes • Consolidated Total Income of INR 37,714 million, grew by 12.6% y-o-y. The growth was primarily driven by increase in patient volumes • EBITDA was INR 9,562 million, growth of 9.4% y-o-y. EBITDA mar
Slide 15: FY2025 performance summary: net cash position
FY2025 performance summary Net cash Positon of INR 8,123 million. Well capitalized balance sheet with strong EBITDA to cash flow conversion Key Highlights INR million FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 Gross Debt 6,219 6,446 8,379 8,422 4,193 3,279 • Gross Debt reduced by INR 914 million Cash
Slide 16: Key operating metrics: Revenue and profitability
Key operating metrics: Revenue and profitability Consistently delivering strong CAGR growth across key financial metrics Total Income (INR million) EBITDA (INR million and margin %) FY2021-25 CAGR2: 26% FY2021-25 CAGR2: 44% +12.6% FY2020-25 CAGR: 20% FY2020-25 CAGR: 33% +9.4% 37,714 33,498 9,562 8,7
Slide 17: Key operating metrics: Volumes, occupancies, ALOS
Key operating metrics: Volumes, occupancies, ALOS Strong volume growth, increased bed capacity and improvements in ALOS Census and occupied beds ALOS (days) +10.1% 3.89 -1.9% 3.76 2,440 3.25 3.23 2,049 2,231 +9.4% 3.17 1,779 1,579 1,514 1,205 1,375 1,076 814 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021
Slide 18: Key operating metrics: ARPOB and revenue mix
Key operating metrics: ARPOB and revenue mix IPD Revenue mix by payor is changing due to uptick in scheme business at Patna and Lucknow ARPOB* (INR) IPD Revenue mix by payor category** +1.3% 59,098 61,890 62,722 54,547 47,731 62% 60% 63% 61% 57% 23% 25% 24% 3% 24% 25% 4% 4% 4% 4% 9% 2% 9% 2% 9% 2% 9
Slide 19: Diverse revenue mix across all complex specialties
Diverse revenue1 mix across all complex specialties Significant contribution from complex specialties, cancer contribution is increasing Heart 20.6% 20.9% 23.8% 23.1% 21.6% Digestive 11.7% 10.2% 11.3% 12.0% 11.4% 10.8% Cancer 12.3% 13.7% 11.5% 12.3% 11.2% Neuro 10.5% 11.4% 11.2% 11.4% 7.2% Kidney &
Slide 20: Volume led growth in both mature and developing hospitals
Volume led growth in both mature and developing hospitals Patna delivered robust growth during the year, offset by subdued performance in Lucknow during H1 FY25 Matured hospitals - Over 6 years Developing hospitals - Less than 6 years Total Income (INR million) EBITDA (INR million and margin %) Tota
Slide 21: Q4 FY2025 Performance Update
03 Q4 FY2025 Performance Update 20
Slide 22: Q4 FY2025 performance summary
Q4 FY2025 performance summary Delivered strong Revenue and EBITDA y-o-y growth of 14% and 20% respectively, led by volume growth Adjusted PAT* INR 9,542 million INR 2,476 million INR 1,014 million INR 1,387 million Total Income Margin: 26.0% Margin: 10.6% Margin: 14.5% EBITDA PAT Q4 FY24 Q4 FY24 Q4
Slide 23: Q4 FY2025 performance summary
Q4 FY2025 performance summary Quarter performance led by strong growth in developing units • Consolidated Total Income of INR 9,542 million, grew by 14.1% y-o-y, primarily led by patient volume growth • EBITDA was INR 2,476 million, growth of 19.8% y-o-y. EBITDA margins improved from 24.7% in Q4 FY2
Slide 24: Key operating metrics: Revenue and profitability
Key operating metrics: Revenue and profitability Registered strong Total Income and EBITDA y-o-y growth of 14% and 20% respectively in Q4 FY25 Total Income (INR million) EBITDA (INR million and margin %) +14.1% +19.8% 9,595 9,542 8,361 2,538 2,476 2,068 Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY2
Slide 25: Key operating metrics: Volumes, occupancies, ALOS
Key operating metrics: Volumes, occupancies, ALOS Strong volume growth, increased bed capacity and improvements in ALOS Census and occupied beds ALOS (days) +13.2% -2.4% 2,480 2,480 3.27 3.23 3.19 2,256 +9.9% 1,577 1,518 1,341 Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 59% 64% 61% Census beds O
Slide 26: Key operating metrics: ARPOB and revenue mix
Key operating metrics: ARPOB and revenue mix ARPOB marginally grow due to change in speciality mix ARPOB* (INR) IPD Revenue mix by payor category +0.9% 63,063 61,307 63,629 59% 55% 57% 24% 27% 25% 4% 5% 9% 3% 10% 3% 10% 4% 4% Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 Cash TPA CGHS/ ECHS/ India
Slide 27: Growth seen in both mature and new hospitals
Growth seen in both mature and new hospitals Developing hospitals continues to deliver strong revenue and EBITDA growth Matured hospitals - Over 6 years Developing hospitals - Less than 6 years Total Income (INR million) EBITDA (INR million and margin %) Total Income (INR million) EBITDA (INR millio
Slide 28: Project Update and Capex Plan
04 Project Update and Capex Plan 27
Slide 29: Noida hospital construction update
Noida hospital construction update 97% superstructure complete; MEP work in progress. Expected to commence operations in Q2 FY26 • Project situated in sector 50 Noida, close proximity to metro station • Greenfield project, with bed capacity of 550 beds • Construction started in September 2022 • Mech
Slide 30: Medanta to enter Mumbai market with 500+ bed hospital at Oshiwara
Medanta to enter Mumbai market with a state-of-the-art, 500+ bedded super-specialty hospital at Oshiwara, Mumbai Super specialty hospital in Oshiwara, Mumbai The Company has bought 8,859 sq. meters of land in Oshiwara from MHADA for an amount of INR 125.11 crores in a public auction In addition,
Slide 31: Delhi: Strengthening our presence with ~1,150 planned beds
Delhi: Strengthening our presence in the region with a planned capacity of ~1,150 beds Expanding into the high-growth, densely populated micro markets of Northwest and South Delhi Super specialty hospital in North West Delhi Super specialty hospital in South Delhi *The artistic image for illustratio
Slide 32: Completing the campus
Completing the campus Establishing world class medical college and guest house for out of city patients Medanta Medical College Medanta Guest House *The artistic image for illustration purposes only *The artistic image for illustration purposes only • Medanta to construct a service apartments / gues
Slide 33: On-going expansion projects
On-going expansion projects Planned bed capacity addition; well positioned to drive near term growth Number of installed beds ~2,000 bed addition +50.3% 400 ~1,000 bed addition 750 ~219 bed addition +33.9% 400 500 +7.8% 100 50 250 100 100 2,823 110 22 300 6,124 49 58 112 3,042 4,074 31-Mar-24Gurugra
Slide 34: Capex plan next 5 years
Capex plan next 5 years Total capex of over ~INR 3,500 crores planned for next 5 years for ~3,000 bed addition 250 300 510 587 4,051 1,063 3,501 300 459 450 109 23 Maintenance Ranchi Lucknow Noida South Mumbai Pitampura, Guwahati Medical Guest Total Capex for 3 New and Patna Delhi- DLF Delhi School
Slide 35: Medanta's Journey, Purpose and Model of Healthcare
Medanta’s Journey, Purpose and 05 Model of Healthcare 34
Slide 36: Medanta was founded to bring a new type of healthcare to India
Medanta was founded to bring a new type of healthcare to India… … the human side of healthcare Healthcare is never only about science. It is also about the art of medicine – the human connection, putting the patient first, collaboration, the personal acts of empathy and the values that guide our dec
Slide 37: Growth from a single flagship hospital in Gurgaon
Growth from a single flagship hospital in Gurgaon… …to a network of 5 high quality hospitals across north India 2026E MEDANTA 2025 HOSPITAL MEDANTA NOIDA 2021 HOSPITAL Plan for 550 beds JAI PRABHA Ranchi** Expected to 2019 MEDANTA SPECIALTY begin phase I 110 Beds MEDANTA HOSPITAL operations with Exp
Slide 38: From our flagship Medicity campus we have grown to ~3,042 beds across 5 cities
From our flagship Medicity campus in Gurgaon, we have grown to ~3,042 beds across 5 cities Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar Gurgaon LUCKNOW PATNA 1,440 beds; 316 ICU beds 757 beds; 202 ICU beds (950 planned) 470 beds; 140 ICU beds (650
Slide 39: Our Mission and Values
Our Mission and Values Embracing a new era and redefining our purpose Core Values Patient centric care: Foster a culture where every one of us is MISSION committed to care for patients and their caregivers Our mission is to deliver Leadership and quality: Commit to delivering excellence in world cla
Slide 40: The Medanta Model of Healthcare
The Medanta Model of Healthcare Delivering the highest quality of medicine with care and compassion Exceptional clinical talent What it means for patients and caregivers? • Super specialized doctors provide the highest quality of care through a team based integrated approach Trust based compassionat
Slide 41: Exceptional clinical talent delivering the highest end of care
Exceptional clinical talent delivering the highest end of care World leading clinicians deliver multispecialty integrated care through a doctor led model 1 Clinical team includes recipients of Padma Bhushan, 5 Almost all doctors work full-time and exclusively at Padma Shri, and BC Roy awards, in add
Slide 42: Infrastructure designed to create a safe and efficient environment
Infrastructure designed to create a safe and efficient environment World class infrastructure that creates the best possible space for healing • High proportion of OTs and ICUs; given the orientation towards higher end, complex clinical work • High focus on infection control practices; dedicated Air
Slide 43: High standard of care enabled by the latest sophisticated technology
High standard of care enabled by the latest sophisticated technology Providing the latest tools to enable our doctors to deliver the greatest care Artis-Zeego Da Vinci Robotic Endovascular Biplane Cath Lab System Surgical Cath Lab Enables cardiologists and Enables surgeons to Used for highly surgeon
Slide 44: Experienced senior management team across units
Experienced senior management team across units Clinical department heads chair operating and governance committees in each unit Dr Naresh Trehan Pankaj Sahni Yogesh Kumar Gupta Chairman and Group CEO & Chief Financial Officer Managing Director Director Bhuvander Kaul Dr Sandeep Sawhney Rajiv Sikka
Slide 45: Eminent Board of Directors
Eminent Board of Directors Marquee domestic and foreign institutions as major shareholders Others Board of Directors 10.25% Promoter FII 33.03% 11.76% Shareholding Mutual Funds pattern as on 10.36% Dr Naresh Trehan Pankaj Sahni Sunil Sachdeva 31st March, 2025 Chairman and Group CEO & Director Non-Ex
Slide 46: Medanta is well placed to deliver sustainable growth
Medanta is well placed to deliver sustainable growth… …while maintaining its core values of patient centric care and clinical leadership and quality CONTINUITY OF CARE TECHNOLOGY Extend clinical THOUGHT ADVANCEMENT services outside LEADERSHIP Use technology to hospital and ENHANCE Build on our impro
Slide 47: Aligning strategy with values to deliver positive results
Aligning strategy with values to deliver positive results for all stakeholders Growth you can be proud of • Deliver the highest end of patient centric care by embracing the sickest patients and treating the most complex cases • Maintain our leadership and quality by strengthening our already excepti
Slide 48: Annexures
06 Annexures 47
Slide 49: Annexure: Profit and Loss Statement
Annexure: Profit and Loss Statement Year End Quarter INR million FY24 FY25 Y-o-Y Growth % Q4 FY24 Q3 FY25 Q4 FY25 Y-o-Y Growth % Revenue from operations 32,751 36,923 12.7% 8,086 9,434 9,312 15.2% Other income 747 791 5.9% 274 160 229 (16.4)% Total income 33,498 37,714 12.6% 8,361 9,595 9,542 14.1%
Slide 50: Annexure: Operational Parameters
Annexure: Operational Parameters Year End Quarter Key metrics FY24 FY25 Y-o-Y Growth % Q4 FY24 Q3 FY25 Q4 FY25 Y-o-Y Growth % Total Beds 2,823 3,042 7.8% 2,823 3,042 3,042 7.8% Census Beds 2,231 2,440 9.4% 2,256 2,480 2,480 9.9% Occupied Bed Days 503,239 552,492 9.8% 121,834 145,095 136,761 12.3% Oc
Slide 51: Annexure: Abbreviations and Definitions
Annexure: Abbreviations and Definitions Abbreviations INR : Indian Rupee NABH : National Accreditation Board for Hospitals & Healthcare Providers NABL : National Accreditation Board for Testing and Calibration Laboratories JCI : Joint Commission International OPD : Out-Patient Department
Slide 52: Contact us
Contact us About Medanta Contact Details Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and Ravi Gothwal – cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest Head of Investor Relations civilian awards in India, a